1. 1. Curtis A, Moore Z, Patton D, O'Connor T, Nugent L. Does using a cellular mobile phone increase the risk of nosocomial infections in the Neonatal Intensive Care Unit: A systematic review. J Neonatal Nurs. 2018;24(5):247-252. 2. Faraji Hormozi S, Saeedi AA, Aminianfar M, Salmani Alishah M, Darvishi M. Study the frequency of Nosocomial Infection and Its relative Factors in the Intensive Care Unit of Hospital based upon the NNI System. Eurasian J Anal Chem. 2018;13(2);em16. 3. Reid R, Sheehy C, Jabbour L. Risk Factors and Interventions Against Nosocomial Infections Across Multiple African Countries: A Systematic Review. CPQ Medicine. 2018;2(2):01-12. 4. Darvishi M. Virulence Factors Profile and Antimicrobial Resistance of Acinetobacter baumannii Strains Isolated from Various Infections Recovered from Immunosuppressive Patients. Biomed Pharmacol J. 2016;9(3):1057-1062. 5. Nazir A, Kadri S. An overview of hospital acquired infections and the role of the microbiology laboratory. International Journal of Research in Medical Sciences. 2014;2(1):21-7. 6. Debnath T, Bhowmik S, Islam T, Hassan Chowdhury MM. Presence of Multidrug-Resistant Bacteria on Mobile Phones of Healthcare Workers Accelerates the Spread of Nosocomial Infection and Regarded as a Threat to Public Health in Bangladesh. J Microsc Ultrastruct. 2018;6(3):165-169. 7. World Health Organization. Prevention of hospital-acquired infections: a practical guide (No. WHO/CDS/CSR/EPH/2002.12). Geneva, Switzerland: World Health Organization. 2002. 8. Samuel SO, Kayode OO, Musa OI, Nwigwe GC, Aboderin AO, Salami TAT, et al. Nosocomial infections and the challenges of control in developing countries. AFR J CLN EXPER MICROBIOL. 2010;11(2):102-110. 9. Barbara J. Stoll infection of Neonatal infects. In: Kliegman R, Richard E. Nelson textbook ofpediatrics, 18th ed. ENGLISH: sandres 2007:798-799. 10. Darvishpoor K, heshmati H, Rezaei Manesh M R, Mir hasani M. Prevalence of nosocomial infections and microbial causes in Torbat heydariyeh 9dey educational and clinical hospital in 2012 and 2013. Iran J Med Microbiol. 2016
2. 10 (1) :93-96. 11. Weber S, Hogardt M, Reinheimer C, Wichelhaus TA, Kempf VAJ, Kessel J, et al. Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases. Ann Hematol. 2019;98(3):763-773. 12. Medina E, Pieper DH. Tackling threats and future problems of multidrug-resistant bacteria. Curr Top Microbiol Immunol. 2016;398:3-33. 13. Bereket W, Hemalatha K, Getenet B, Wondwossen T, Solomon A, Zeynudin A, et al. Update on bacterial nosocomial infections. Eur Rev Med Pharmacol Sci. 2012;16(8):1039-44. 14. Hormozi SF, Vasei N, Aminianfar M, Darvishi M, Saeedi AA. Antibiotic resistance in patients suffering from nosocomial infections in Besat Hospital. Eur J Transl Myol. 2018;28(3):7594. 15. Farzianpour F, Bakhtiari A, Mosavee SH, Akbarzadeh A. The most important species of nosocomial infection and the most important wards susceptible to nosocomial infection. Iran J Public Health. 2014;43(7):1016-7. 16. Falahi J, Khaledi A, Alikhani MY, Taghipour A, Amel JS, Honarmand M, et al. Prevalence of Nosocomial Infection in Different Wards of Ghaem Hospital, Mashhad. Avicenna J Clin Microbiol Infect. 2017;4(2):e40297. 17. De Kraker ME, Davey PG, Grundmann H
3. 5 (3) :7-17 19. Wright SA, Bieluch VM. Selected nosocomial viral infections. Heart and lung: the journal of critical care. 1993;22(2):183-187. 20. Rubin LG, Kohn N, Nullet S, Hill M. Reduction in rate of nosocomial respiratory virus infections in a children's hospital associated with enhanced isolation precautions. Infect Control Hosp Epidemiol. 2018;39(2):152-156. 21. Cavalheiro M, Teixeira MC. Candida Biofilms: Threats, Challenges, and Promising Strategies. Front Med (Lausanne). 2018;5:28. 22. Morens DM, Fauci AS. Emerging infectious diseases: threats to human health and global stability. PLoS pathogens 2013;9(7):e1003467. 23. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P.T. 2015;40(4),277-283. 24. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization, Geneva, Switzerland. 2017. 25. Tatarelli P, Mikulska M. Multidrug-resistant bacteria in hematology patients: emerging threats. Future microbiol. 2016;11(6):767-780. 26. Garoy EY, Gebreab YB, Achila OO, Tekeste DG, Kesete R, Ghirmay R, et al. Methicillin-Resistant Staphylococcus aureus (MRSA): Prevalence and Antimicrobial Sensitivity Pattern among Patients-A Multicenter Study in Asmara, Eritrea. Can J Infect Dis Med Microbiol. 2019;2019:8321834. 27. Nagendra Prasad HS, Karthik CS, Manukumar HM, Mallesha L, Mallu P. New approach to address antibiotic resistance: Miss loading of functional membrane microdomains (FMM) of methicillin-resistant Staphylococcus aureus (MRSA). Microb Pathog. 2019;127:106-115. 28. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005;5(5):275-86. 29. Islam T, Kubra K, Hassan Chowdhury MM. Prevalence of Methicillin-Resistant Staphylococcus aureus in Hospitals in Chittagong, Bangladesh: A Threat of Nosocomial Infection. J Microsc Ultrastruct. 2018;6(4):188-191. 30. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13(12):1840-1846. 31. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46 Suppl 5(Suppl 5):S350-S359. 32. Puchter L, Chaberny IF, Schwab F, Vonberg RP, Bange FC, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control. 2018;7:1. 33. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be?. Cmaj. 2009;180(4):408-415. 34. Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. Asian Pac J Trop Biomed. 2015;5(7):509-514. 35. Yang J, Yuan Y, Tang M, Liu L, Yang K, Liu J. Phenotypic and genetic characteristics of vancomycin-resistant Enterococcus faecium. Microb Pathog. 2019;128:131-135. 36. Jackson SS, Harris AD, Magder LS, Stafford KA, Johnson JK, Miller LG, et al. Bacterial burden is associated with increased transmission to health care workers from patients colonized with vancomycin-resistant Enterococcus. Am J Infect Control. 2019;47(1):13-17. 37. Hammerum AM, Baig S, Kamel Y, Roer L, Pinholt M, Gumpert H, et al. Emergence of vanA Enterococcus faecium in Denmark, 2005-15. J Antimicrob Chemother. 2017;72(8):2184-2190. 38. Bourdon N, Fines-Guyon M, Thiolet JM, Maugat S, Coignard B, Leclercq R, et al. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother. 2011;66(4):713-21. 39. Remschmidt C, Schröder C, Behnke M, Gastmeier P, Geffers C, Kramer TS. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany - 10 years of surveillance. Antimicrob Resist Infect Control. 2018;7:54. 40. Buetti N, Wassilew N, Rion V, Senn L, Gardiol C, Widmer A, et al. Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey. Antimicrob Resist Infect Control. 2019;8(1):16. 41. Ostria-Hernandez ML, Juárez-de la Rosa KC, Arzate-Barbosa P, Lara-Hernández A, Sakai F, Antonio Ibarra J, et al. Nosocomial, Multidrug-Resistant Klebsiella pneumoniae Strains Isolated from Mexico City Produce Robust Biofilms on Abiotic Surfaces but Not on Human Lung Cells. Microb Drug Resist. 2018;24(4):422-433. 42. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Emerging infections program healthcare-associated infections and antimicrobial use prevalence survey team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198-1208. 43. Yasin F, Assad S, Talpur AS, Zahid M, Malik SA. Combination Therapy for Multidrug-Resistant Klebsiella Pneumoniae Urinary Tract Infection. Cureus. 2017;9(7):e1503. 44. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study--authors' responseJ Antimicrob Chemother. 2015;70(7):2133-43. 45. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. 46. Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16(10):749-761. 47. Moradigaravand D, Martin V, Peacock SJ, Parkhill J. Evolution and epidemiology of multidrug-resistant Klebsiella pneumoniae in the United Kingdom and Ireland. MBio. 2017;8(1). pii: e01976-16. 48. Sikarwar AS, Batra HV. Challenge to healthcare: Multidrug resistance in Klebsiella pneumoniae. In 2011 International Conference on Food Engineering and Biotechnology IPCBEE. 2011;9:130-134. 49. Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis. 2019;32(1):69-76. 50. Richet H, Fournier PE. Nosocomial infections caused by Acinetobacter baumannii a major threat worldwide. Infect Control Hosp Epidemiol. 2006;27(7):645-6. 51. Almaghrabi MK, Joseph MRP, Assiry MM, Hamid ME. Multidrug-Resistant Acinetobacter baumannii: An Emerging Health Threat in Aseer Region, Kingdom of Saudi Arabia. Can J Infect Dis Med Microbiol. 2018;2018:9182747. 52. Gonzalez-Villoria AM, Valverde-Garduno V. Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen. J Pathog. 2016;2016:7318075. 53. Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL, et al. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis. 2019;79:179-184. 54. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292-301. 55. Willems S, Kampmeier S, Bletz S, Kossow A, Köck R, Kipp F, et al. Whole-genome sequencing elucidates epidemiology of nosocomial clusters of Acinetobacter baumannii. J Clin Microbiol. 2016;54(9),2391-2394. 56. Howard A, O'Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012;3(3):243-250. 57. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012;39(2):105-14. 58. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43-48. 59. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010;10(4):441-451. 60. Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-resistant pseudomonas infections: hard to treat, but hope on the horizon?. Curr Infect Dis Rep. 2018;20(8):23. 61. Dou Y, Huan J, Guo F, Zhou Z, Shi Y. Pseudomonas aeruginosa prevalence, antibiotic resistance and antimicrobial use in Chinese burn wards from 2007 to 2014. J Int Med Res. 2017;45(3):1124-1137.
4. 1. Curtis A, Moore Z, Patton D, O'Connor T, Nugent L. Does using a cellular mobile phone increase the risk of nosocomial infections in the Neonatal Intensive Care Unit: A systematic review. J Neonatal Nurs. 2018;24(5):247-252. 2. Faraji Hormozi S, Saeedi AA, Aminianfar M, Salmani Alishah M, Darvishi M. Study the frequency of Nosocomial Infection and Its relative Factors in the Intensive Care Unit of Hospital based upon the NNI System. Eurasian J Anal Chem. 2018;13(2);em16. 3. Reid R, Sheehy C, Jabbour L. Risk Factors and Interventions Against Nosocomial Infections Across Multiple African Countries: A Systematic Review. CPQ Medicine. 2018;2(2):01-12. 4. Darvishi M. Virulence Factors Profile and Antimicrobial Resistance of Acinetobacter baumannii Strains Isolated from Various Infections Recovered from Immunosuppressive Patients. Biomed Pharmacol J. 2016;9(3):1057-1062. 5. Nazir A, Kadri S. An overview of hospital acquired infections and the role of the microbiology laboratory. International Journal of Research in Medical Sciences. 2014;2(1):21-7. 6. Debnath T, Bhowmik S, Islam T, Hassan Chowdhury MM. Presence of Multidrug-Resistant Bacteria on Mobile Phones of Healthcare Workers Accelerates the Spread of Nosocomial Infection and Regarded as a Threat to Public Health in Bangladesh. J Microsc Ultrastruct. 2018;6(3):165-169. 7. World Health Organization. Prevention of hospital-acquired infections: a practical guide (No. WHO/CDS/CSR/EPH/2002.12). Geneva, Switzerland: World Health Organization. 2002. 8. Samuel SO, Kayode OO, Musa OI, Nwigwe GC, Aboderin AO, Salami TAT, et al. Nosocomial infections and the challenges of control in developing countries. AFR J CLN EXPER MICROBIOL. 2010;11(2):102-110. 9. Barbara J. Stoll infection of Neonatal infects. In: Kliegman R, Richard E. Nelson textbook ofpediatrics, 18th ed. ENGLISH: sandres 2007:798-799. 10. Darvishpoor K, heshmati H, Rezaei Manesh M R, Mir hasani M. Prevalence of nosocomial infections and microbial causes in Torbat heydariyeh 9dey educational and clinical hospital in 2012 and 2013. Iran J Med Microbiol. 2016; 10
5. (1) :93-96. 11. Weber S, Hogardt M, Reinheimer C, Wichelhaus TA, Kempf VAJ, Kessel J, et al. Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases. Ann Hematol. 2019;98(3):763-773. 12. Medina E, Pieper DH. Tackling threats and future problems of multidrug-resistant bacteria. Curr Top Microbiol Immunol. 2016;398:3-33. 13. Bereket W, Hemalatha K, Getenet B, Wondwossen T, Solomon A, Zeynudin A, et al. Update on bacterial nosocomial infections. Eur Rev Med Pharmacol Sci. 2012;16(8):1039-44. 14. Hormozi SF, Vasei N, Aminianfar M, Darvishi M, Saeedi AA. Antibiotic resistance in patients suffering from nosocomial infections in Besat Hospital. Eur J Transl Myol. 2018;28(3):7594. 15. Farzianpour F, Bakhtiari A, Mosavee SH, Akbarzadeh A. The most important species of nosocomial infection and the most important wards susceptible to nosocomial infection. Iran J Public Health. 2014;43(7):1016-7. 16. Falahi J, Khaledi A, Alikhani MY, Taghipour A, Amel JS, Honarmand M, et al. Prevalence of Nosocomial Infection in Different Wards of Ghaem Hospital, Mashhad. Avicenna J Clin Microbiol Infect. 2017;4(2):e40297. 17. De Kraker ME, Davey PG, Grundmann H; BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8(10):e1001104. 18. Larypoor M, Frsad S. Evaluation of nosocomial infections in one of hospitals of Qom. Iran J Med Microbiol. 2011; 5